BMO Capital Reiterates Outperform Rating on Merus N.V. (MRUS)

Go back to BMO Capital Reiterates Outperform Rating on Merus N.V. (MRUS)

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

May 23, 2024 5:00 PM UTC

MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT

MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster presentation: June 3, 2024, 1:30-4:30 p.m. CT

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a... More

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

May 23, 2024 5:00 PM UTC

-   60% response rate observed among 10 evaluable patients

-   Favorable safety profile in 26 patients enrolled as of the abstract cutoff date, with no significant overlapping toxicities observed

-   Conference call on Tuesday, May 28 at 8:00 a.m. ET to discuss full ASCO® data set

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:... More